Targeting NFkappaB protects tendons from injury
Researchers from the UK and the US have prevented tendon injury and degeneration by simply blocking a key signalling pathway in inflammation.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2129 entries already.
Entries by Thomas Gabrielczyk
Anaveon bags CHF35m series A financing
University Zurich spin-off Anaveon AG announced it will proceeds from its financing round to push development of its preclinical IL-2-receptor agonist.
AMR network CARB-X expands reach
The global antibacterial innovation network CARB-X has expanded its reach by adding six new life-science organisations to its fight against antimicrobial resistance (AMR).
Roche swallows Spark Therapeutics in $4.3bn deal
Swiss pharma giant Roche has complemented its drug pipeline in the lucrative hemophilia A market by taking over hemophilia A gene therapy developer Spark Therapeutics for US$4.3bn.
How salt triggers allergy
Sodium chloride can promote immune responses that have been linked to atopic dermatitis. Researchers have now unraveled the mechanistic details between salt intake and activation of T cells.
Calypso Biotech cash in €20M Series A financing
Dutch autoimmunity specialist Calypso Biotech BV has raised €20m in a Series A financing co-led by Gilde Healthcare and Inkef Capital and co-financed by Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and the company’s seed investor M Ventures.
Evotec and HZI join forces in antibiotics discovery
Evotec AG and the Helmholtz Centre for Infection Research (HZI) have joined platforms in order to find novel resistance-breaking antibiotics against Gram-negative bugs.
First immunotolerant allogenic cell transplants revealed
Researchers for the first time have found a way to prevent immune rejection of allogenic iPSC-derived cell and tissue transplants.
Digital solutions to serialisation
Its only been nine years since the first blockchain technology applications in finance were introduced. Big players are now working to use distributed computing to protect pharma logistics from counterfeit drugs. Unlike current Internet-based solutions, the decentralised blockchain network is immune to manipulation or hacks, as transactions can be verified, recorded, and coordinated autonomously without third-party involvement.
Arvelle Therapeutics raises $180m in Series A financing
Swiss newco Arvelle Therapeutics has baged a $180m (€159.1m) series A financing led by LSP. The company licenced the anti-epileptic candidate cenobamate (YKP3089) for $100m (€88.4m) upfront from SK Biopharmaceuticals.